Dyslipidaemia and stroke: how low should we go?

Guilherme Gama

From the Porto University Center of Medicine Stroke Update Course, Porto, Portugal. 26–27 June 2018.

Abstract

My aim is to review the latest evidence on dyslipidaemia and stroke. Stroke is a heterogeneous disorder and so should be our prescription of antilipidaemic medication. In recent years, new pharmacological therapeutics were developed, making the statins paradigm look "old". We think both worlds need not collide, albeit working together for a more adequate treatment of our "pathies". It is, however, important to remember that we need new drugs for achieving cholesterol goals but we do not need new goals just because there are new drugs.